复星医药:控股子公司与Sandoz AG达成至多10款生物类似药许可合作,首批3款产品首付款及里程碑款至多2.37亿美元

智通财经
Aug 17
【复星医药:控股子公司与Sandoz AG达成至多10款生物类似药许可合作,首批3款产品首付款及里程碑款至多2.37亿美元】复星医药公告,公司控股子公司复宏汉霖与Sandoz AG签订《合作框架协议》,可就复宏汉霖至多10款单克隆抗体和/或抗体偶联药物生物类似药产品或成分开展海外许可合作,并已就首批3款合作产品达成具体商业条款,Sandoz AG将就首批3款产品支付至多2.37亿美元的首付款、开发里程碑及开发预算里程碑款项,并支付至多7700万美元的销售里程碑款项及按净销售额或净利润40%的销售分成。此外,Sandoz AG已就1款潜在合作产品支付800万美元选择权费。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10